In a press release, Ember said it looks to leverage findings in brown-fat biology and recent breakthroughs in selective insulin sensitivity to develop treatments for metabolic diseases, including Type 2 diabetes and obesity.
Third Rock Ventures launches Ember Therapeutics
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week